Tumor vessel co-option probed by single-cell analysis.
anti-angiogenic therapy
cancer cells
endothelial cells
macrophages
metastasis
pericytes
resistance
single-cell RNA sequencing
tumor angiogenesis
tumor vessel co-option
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
15 06 2021
15 06 2021
Historique:
received:
18
10
2020
revised:
16
05
2021
accepted:
25
05
2021
entrez:
16
6
2021
pubmed:
17
6
2021
medline:
11
2
2022
Statut:
ppublish
Résumé
Tumor vessel co-option is poorly understood, yet it is a resistance mechanism against anti-angiogenic therapy (AAT). The heterogeneity of co-opted endothelial cells (ECs) and pericytes, co-opting cancer and myeloid cells in tumors growing via vessel co-option, has not been investigated at the single-cell level. Here, we use a murine AAT-resistant lung tumor model, in which VEGF-targeting induces vessel co-option for continued growth. Single-cell RNA sequencing (scRNA-seq) of 31,964 cells reveals, unexpectedly, a largely similar transcriptome of co-opted tumor ECs (TECs) and pericytes as their healthy counterparts. Notably, we identify cell types that might contribute to vessel co-option, i.e., an invasive cancer-cell subtype, possibly assisted by a matrix-remodeling macrophage population, and another M1-like macrophage subtype, possibly involved in keeping or rendering vascular cells quiescent.
Identifiants
pubmed: 34133923
pii: S2211-1247(21)00618-5
doi: 10.1016/j.celrep.2021.109253
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109253Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interest The authors declare no competing interests.